Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020
Fourth-quarter 2019 revenue estimated to be approximately $23.7 million Full-year 2019 revenue estimated to be approximately $73 million , representing year-over-year growth of more than 220% Flexion provides 2020 product revenue guidance of $120 million to $135 million BURLINGTON, Mass. , Jan.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label
Conference call scheduled for Friday, December 27, 2019 at 8:00 a.m. ET BURLINGTON, Mass. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update
View HTML
Toggle Summary Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis
BURLINGTON, Mass. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with
View HTML
Toggle Summary Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder
BURLINGTON, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020 . Dr. Bodick co-founded Flexion in 2007 with Michael Clayman, M.D., the company’s President
View HTML
Toggle Summary Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain
NFL broadcaster Solomon Wilcots to go “Knee to Knee” as moderator of discussion with 1980 USA hockey team captain Mike Eruzione, NFL Hall of Fame member Rod Woodson and retired MLB player Chris Dickerson Orthopaedic Summit is the premier gathering of sports medicine and arthroscopic orthopedists
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings
Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scales In this analysis of concordant pain reporters, ZILRETTA provided durable pain relief that was statistically significant and
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights
Company reported ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2 Full-year 2019 ZILRETTA net sales guidance range tightened to $70 million to $75 million Flexion initiated Phase 2 trial investigating
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500 restricted stock units. The Compensation Committee of the Board of Directors
View HTML